HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients

Monique C. Minnema; Kazem Nasserinejad; Ute Hegenbart; Paula F. Ypma; Ka Lung Wu; Marie Jose Kersten; Sandra Croockewit; Sonja Zweegman; Lidwine Tick; Annemiek Broijl; Harry Koene; Gerard M. J. Bos; Pieter Sonneveld; Stefan O. Schonland

doi:10.1002/jha2.918

HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients

Monique C. Minnema^*, Kazem Nasserinejad, Ute Hegenbart, Paula F. Ypma, Ka Lung Wu, Marie Jose Kersten, Sandra Croockewit, Sonja Zweegman, Lidwine Tick, Annemiek Broijl, Harry Koene, Gerard M. J. Bos, Pieter Sonneveld, Stefan O. Schonland

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The HOVON 104 studied bortezomib-dexamethasone induction therapy and autologous stem cell transplantation in 50 patients, of whom 35 received an autologous stem cell transplantation (ASCT). We demonstrate a 5-year overall survival (OS) of 73% and progression-free survival (PFS) of 52% for all 50 patients with a median follow-up of 61.3 months. For the 35 transplanted patients, calculated from the date of ASCT, the 5-year OS and PFS were 91% and 68%, respectively. After ASCT, the rate of organ response improved over time but stabilized around 3 years. A complete cardiac response was seen in around 60% of patients and remained stable from 2 years onward. Reaching complete renal response was slower over time and achieved by 61% of the renal-affected patients at 5 years. We confirm the excellent outcomes after ASCT and demonstrate a 60% complete organ response with longer follow-up.

Original language	English
Pages (from-to)	815-819
Number of pages	5
Journal	eJHaem
Volume	5
Issue number	4
Early online date	1 Jun 2024
DOIs	https://doi.org/10.1002/jha2.918
Publication status	Published - Aug 2024

Keywords

amyloidosis
chemotherapy
SCT
TRIAL

Access to Document

10.1002/jha2.918Licence: CC BY-NC-ND

Cite this

Minnema, M. C., Nasserinejad, K., Hegenbart, U., Ypma, P. F., Wu, K. L., Kersten, M. J., Croockewit, S., Zweegman, S., Tick, L., Broijl, A., Koene, H., Bos, G. M. J., Sonneveld, P., & Schonland, S. O. (2024). HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients. eJHaem, 5(4), 815-819. https://doi.org/10.1002/jha2.918

@article{7c8f2c44d759498a9dd55b2ae209b09f,

title = "HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients",

abstract = "The HOVON 104 studied bortezomib-dexamethasone induction therapy and autologous stem cell transplantation in 50 patients, of whom 35 received an autologous stem cell transplantation (ASCT). We demonstrate a 5-year overall survival (OS) of 73% and progression-free survival (PFS) of 52% for all 50 patients with a median follow-up of 61.3 months. For the 35 transplanted patients, calculated from the date of ASCT, the 5-year OS and PFS were 91% and 68%, respectively. After ASCT, the rate of organ response improved over time but stabilized around 3 years. A complete cardiac response was seen in around 60% of patients and remained stable from 2 years onward. Reaching complete renal response was slower over time and achieved by 61% of the renal-affected patients at 5 years. We confirm the excellent outcomes after ASCT and demonstrate a 60% complete organ response with longer follow-up.",

keywords = "amyloidosis, chemotherapy, SCT, TRIAL",

author = "Minnema, {Monique C.} and Kazem Nasserinejad and Ute Hegenbart and Ypma, {Paula F.} and Wu, {Ka Lung} and Kersten, {Marie Jose} and Sandra Croockewit and Sonja Zweegman and Lidwine Tick and Annemiek Broijl and Harry Koene and Bos, {Gerard M. J.} and Pieter Sonneveld and Schonland, {Stefan O.}",

year = "2024",

month = aug,

doi = "10.1002/jha2.918",

language = "English",

volume = "5",

pages = "815--819",

journal = "eJHaem",

issn = "2688-6146",

publisher = "John Wiley & Sons Inc.",

number = "4",

}

Minnema, MC, Nasserinejad, K, Hegenbart, U, Ypma, PF, Wu, KL, Kersten, MJ, Croockewit, S, Zweegman, S, Tick, L, Broijl, A, Koene, H, Bos, GMJ, Sonneveld, P & Schonland, SO 2024, 'HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients', eJHaem, vol. 5, no. 4, pp. 815-819. https://doi.org/10.1002/jha2.918

TY - JOUR

T1 - HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients

AU - Minnema, Monique C.

AU - Nasserinejad, Kazem

AU - Hegenbart, Ute

AU - Ypma, Paula F.

AU - Wu, Ka Lung

AU - Kersten, Marie Jose

AU - Croockewit, Sandra

AU - Zweegman, Sonja

AU - Tick, Lidwine

AU - Broijl, Annemiek

AU - Koene, Harry

AU - Bos, Gerard M. J.

AU - Sonneveld, Pieter

AU - Schonland, Stefan O.

PY - 2024/8

Y1 - 2024/8

N2 - The HOVON 104 studied bortezomib-dexamethasone induction therapy and autologous stem cell transplantation in 50 patients, of whom 35 received an autologous stem cell transplantation (ASCT). We demonstrate a 5-year overall survival (OS) of 73% and progression-free survival (PFS) of 52% for all 50 patients with a median follow-up of 61.3 months. For the 35 transplanted patients, calculated from the date of ASCT, the 5-year OS and PFS were 91% and 68%, respectively. After ASCT, the rate of organ response improved over time but stabilized around 3 years. A complete cardiac response was seen in around 60% of patients and remained stable from 2 years onward. Reaching complete renal response was slower over time and achieved by 61% of the renal-affected patients at 5 years. We confirm the excellent outcomes after ASCT and demonstrate a 60% complete organ response with longer follow-up.

AB - The HOVON 104 studied bortezomib-dexamethasone induction therapy and autologous stem cell transplantation in 50 patients, of whom 35 received an autologous stem cell transplantation (ASCT). We demonstrate a 5-year overall survival (OS) of 73% and progression-free survival (PFS) of 52% for all 50 patients with a median follow-up of 61.3 months. For the 35 transplanted patients, calculated from the date of ASCT, the 5-year OS and PFS were 91% and 68%, respectively. After ASCT, the rate of organ response improved over time but stabilized around 3 years. A complete cardiac response was seen in around 60% of patients and remained stable from 2 years onward. Reaching complete renal response was slower over time and achieved by 61% of the renal-affected patients at 5 years. We confirm the excellent outcomes after ASCT and demonstrate a 60% complete organ response with longer follow-up.

KW - amyloidosis

KW - chemotherapy

KW - SCT

KW - TRIAL

U2 - 10.1002/jha2.918

DO - 10.1002/jha2.918

M3 - Article

SN - 2688-6146

VL - 5

SP - 815

EP - 819

JO - eJHaem

JF - eJHaem

IS - 4

ER -

HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this